GRAL

GRAIL, Inc. operates as a healthcare company focused on early cancer detection through blood testing technology. Headquartered in Menlo Park, California, the company develops and commercializes multi-cancer early detection tests using next-generation sequencing and machine learning algorithms. GRAIL's flagship product, Galleri, is a blood-based screening test designed to detect multiple types of cancer, many of which lack standard screening methods, often before symptoms appear. The test analyzes cell-free DNA in the bloodstream to identify cancer signals and predict the tissue of origin. The company was founded in 2016 as a spin-off from Illumina, Inc., which later reacquired GRAIL in 2021 for approximately $7.1 billion, though the acquisition faced significant regulatory scrutiny from the Federal Trade Commission and European Commission. In 2023, following an FTC order, Illumina began the process of divesting GRAIL as a separate entity. GRAIL employs over 1,500 people and operates laboratories and offices across the United States and internationally. The company targets healthcare providers, health systems, and self-pay consumers, positioning its technology as a complement to existing single-cancer screening programs. GRAIL continues to conduct clinical studies and pursue regulatory pathways while expanding commercial availability of its testing services in select markets.